Factor XIII Val34Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome

Lupus

Volumn 13, Issue 1, 2004, Pages 32-35

  Diz Kucukkaya, Reyhan ^a,b   Hancer, V S ^a   Inanc, M ^a   Nalcaci, M ^a   Pekcelen, Y ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Istanbul Faculty of Medicine ^*  (Turkey)

Author keywords

Antiphospholipid syndrome; Factor XIII Val34Leu polymorphism; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 13; LEUCINE; MUTANT PROTEIN; PROTEIN SUBUNIT; THROMBIN; VALINE;

ABORTION; ADOLESCENT; ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS; VEIN THROMBOSIS;

ADOLESCENT; ADULT; ANTIPHOSPHOLIPID SYNDROME; FACTOR XIII; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LEUCINE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; VENOUS THROMBOSIS;

EID: 1642419086     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu479oa     Document Type: Article

References (28)

1. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-1311.
2. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691.
3. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-107.
4. Oosting JD, Derksen RH, Robbink IW, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with thrombin, protein C, or protein S: An explanation for their pathogenic mechanism? Blood 1993; 81: 2618-2625.
5. Ames PR, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies-a crucial role for acquired free protein S deficiency. Thromb Haemost 1996; 76: 190-194.
6. Khamashta MA. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. J Autoimmun 2000; 15: 249-253.
7. Ames PR, Tommasino C, D'Andrea G, Iannaccone L, Brancaccio V, Margaglione M. Thrombophilic genotypes in subjects with idiophatic antiphospholipid antibodies. Prevalance and significance. Thromb Haemost 1998; 79: 46-49.
8. 506 → GIn mutation in patients with antiphospholipid antibodies. Lupus 1996; 5: 303-306.
9. Yee VC, Pedersen LC, Le Trong I, Bishop PD, Stenkamp RE, Teller DC. Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proc Natl Acad Sci USA 1994; 91: 7296-7300.
10. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorhism in the factor XIII gene with venous thrombosis. Blood 1999; 93: 906-908.
11. Franco RF, Reitsma PH, Lourenco D, Maffei FH, Morelli V, Tavella MH et al. Factor XIII Val34Leu is a genetic factor involved in the aetiology of venous thrombosis. Thromb Haemost 1999; 81: 676-679.
12. Renner W, Koppel H, Hoffman C, Schallmoser K, Stanger O, Toplak H et al. Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: Common mutations of blood coagulation factors and deep vein thrombosis in Austria. Thromb Research 2000; 99: 35-39.
13. Kohler HP, Stickland MH, Ossei-Geming N, Carter A, Mikkola H, Grant PJ. Association of a common polymorhism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
14. Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-591.
15. Gemmati D, Serino ML, Ongaro A, Tognazzo S, Moratelli S, Resca R et al. A common mutation in the gene for coagulation factor XIII-A (Val34Leu): A risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am J Hematol 2001; 67: 183-188.
16. Franco RF, Pazin-Filho A, Tavella MH, Simoes MV, Marin-Neto JA, Zago MA. Factor XIII Val34Leu and risk of myocardial infarction. Haematologica 2000; 85: 67-71.
17. Wartiovaara U, Perola M, Mikkola H, Totterman K, Savolainen V, Penttila A et al. Association of factor XIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis 1999; 142: 295-300.
18. Brandt JT, Triplett DA, Alving B, Scharer I. Criteria for the diagnosis of lupus anticoagulants: An update. Thromb Haemost 1995; 74: 1185-1187.
19. Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9.
20. Aleksic N, Ahn C, Wang YW, Juneja H, Folsom AR, Boerwinkle E et al. Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease. Arterioscler Thromb Vasc Biol 2002; 22: 384-352.
21. Cho KH, Kim BC, Kim MK, Shin BA. No association of factor XIII Val34Leu polymorphism with primary intracerebral hemorrhage and healthy controls in Korean population. J Korean Med Sci 2002; 17: 249-253.
22. Corral J, Gonzales-Conejero R, Iniesta JA, Rivera J, Martinez C, Vicente V. The factor XIII Val34Leu polymorphism in venous and arterial thrombosis. Haematologica 2000; 85: 293-297.
23. Balogh I, Szoke G, Karpati L, Wartiovaara U, Katona E, Komaromi I et al. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology. Blood 2000; 86: 2479-2486.
24. Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998; 92: 2766-2770.
25. Ariens RAS, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-995.
26. Wartiovaara U, Mikkola H, Szoke G, Haramura G, Karpati L, Balogh I et al. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. Thromb Haemost 2000; 84: 595-600.
27. Anwar R, Gallivan L, Edmonds ST, Markham AF. Genotype/phenotype correlations for coagulation factor XIII: Specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood 1999; 93: 897-905.
28. Wilmer M, Rudin K, Kolde H, Poetzsch B, Lenz W, Moessmer G et al. Evaluation of a sensitivie colorimetric FXIII incorporation assay. Effects of FXIII Val34Leu, plasma fibrinogen concentration and congenital FXIII deficiency. Thrombosis Res 2001; 102: 81-91.